• Tenaya Therapeutics entered a lease termination agreement for its Union City, California genetic medicines manufacturing site.
• Lease end moved to Aug. 31, 2026 from July 2031; covers about 94,046 rentable square feet.
• Termination cost includes forfeiting a USD 1.75 million security deposit; one-time termination fee of about USD 294,200.
• Facility was decommissioned in 2025 as part of cost cuts; existing TN-201 and TN-401 inventory supports ongoing clinical trials.
• Company plans to transfer its AAV manufacturing process to a global contract development manufacturing organization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-294879), on July 02, 2026, and is solely responsible for the information contained therein.